Your browser doesn't support javascript.
loading
Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial.
Qadri, Firdausi; Akhtar, Marjahan; Bhuiyan, Taufiqur R; Chowdhury, Mohiul I; Ahmed, Tasnuva; Rafique, Tanzeem A; Khan, Arifuzzaman; Rahman, Sadia I A; Khanam, Farhana; Lundgren, Anna; Wiklund, Gudrun; Kaim, Joanna; Löfstrand, Madeleine; Carlin, Nils; Bourgeois, A Louis; Maier, Nicole; Fix, Alan; Wierzba, Thomas; Walker, Richard I; Svennerholm, Ann-Mari.
Afiliação
  • Qadri F; International Centre for Diarrhoeal Disease Research Bangladesh, Dhaka, Bangladesh.
  • Akhtar M; International Centre for Diarrhoeal Disease Research Bangladesh, Dhaka, Bangladesh.
  • Bhuiyan TR; International Centre for Diarrhoeal Disease Research Bangladesh, Dhaka, Bangladesh.
  • Chowdhury MI; International Centre for Diarrhoeal Disease Research Bangladesh, Dhaka, Bangladesh.
  • Ahmed T; International Centre for Diarrhoeal Disease Research Bangladesh, Dhaka, Bangladesh.
  • Rafique TA; International Centre for Diarrhoeal Disease Research Bangladesh, Dhaka, Bangladesh.
  • Khan A; International Centre for Diarrhoeal Disease Research Bangladesh, Dhaka, Bangladesh.
  • Rahman SIA; International Centre for Diarrhoeal Disease Research Bangladesh, Dhaka, Bangladesh.
  • Khanam F; International Centre for Diarrhoeal Disease Research Bangladesh, Dhaka, Bangladesh.
  • Lundgren A; Gothenburg University Vaccine Research Institute, Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
  • Wiklund G; Gothenburg University Vaccine Research Institute, Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
  • Kaim J; Gothenburg University Vaccine Research Institute, Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
  • Löfstrand M; Gothenburg University Vaccine Research Institute, Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
  • Carlin N; Scandinavian Biopharma, Solna, Sweden.
  • Bourgeois AL; PATH, Washington DC, USA.
  • Maier N; PATH, Washington DC, USA.
  • Fix A; PATH, Washington DC, USA.
  • Wierzba T; PATH, Washington DC, USA; Wake Forest School of Medicine, Section on Infectious Diseases, Department of Internal Medicine, Winston Salem, NC, USA.
  • Walker RI; PATH, Washington DC, USA.
  • Svennerholm AM; Gothenburg University Vaccine Research Institute, Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden. Electronic address: ann-mari.svennerholm@microbio.gu.se.
Lancet Infect Dis ; 20(2): 208-219, 2020 02.
Article em En | MEDLINE | ID: mdl-31757774
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas de Produtos Inativados / Vacinas contra Escherichia coli / Escherichia coli Enterotoxigênica / Formação de Anticorpos Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas de Produtos Inativados / Vacinas contra Escherichia coli / Escherichia coli Enterotoxigênica / Formação de Anticorpos Idioma: En Ano de publicação: 2020 Tipo de documento: Article